HYPERRAB Solution for injection Ref.[10828] Active ingredients: Human rabies immunoglobulin

Source: FDA, National Drug Code (US)  Revision Year: 2019 

1. Indications and Usage

HYPERRAB is a human rabies immune globulin indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitation of Use:

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.(1-3)

For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of post-exposure prophylaxis.(1-3)

Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

2. Dosage and Administration

For infiltration and intramuscular use only.

The strength of HYPERRAB is 300 IU/mL.

2.1 Dose

Use HYPERRAB in combination with rabies vaccine series to be effective. Do not use HYPERRAB alone for prevention.

Administer HYPERRAB within 7 days after the first dose of rabies vaccine.

Rabies Postexposure Prophylaxis Schedule*:

Vaccination StatusTreatmentRegimen
Not previously vaccinated Wound cleansing • Cleanse all wounds immediately and thoroughly with
soap and water.
• Irrigate the wounds with a virucidal agent
such as a povidone-iodine solution, if available.
HYPERRAB
20 IU/kg body weight
OR
0.0665 mL/kg body weight

Single-dose
• Administer HYPERRAB as soon as possible
after exposure, preferably at the time of the first vaccine dose.
• Infiltrate the full dose of HYPERRAB thoroughly in
the area around and into the wound(s), if anatomically
feasible [see Dosage and Administration (2.3)].
• Inject the remainder, if any, intramuscularly at an
anatomical site distant from the site of vaccine
administration [see Dosage and Administration (2.3)].
• Do not exceed the recommended dose of
HYPERRAB, otherwise the active production of rabies
antibody may be partially suppressed [see Drug Interactions (7)].
• Use separate syringes, needles, and anatomical
injection sites for HYPERRAB and for rabies vaccine.
Rabies Vaccine • Administer rabies vaccine on day 0
• Complete a rabies vaccination series for previously
unvaccinated persons.
Previously vaccinated§ Wound cleansing • Cleanse all wounds immediately and thoroughly with
soap and water.
• Irrigate the wounds with a virucidal agent such as a
povidone-iodine solution, if available.
HYPERRAB • Do not administer HYPERRAB [see Indications and Usage (1)].
Rabies Vaccine • Administer rabies vaccine on day 0.
• Complete a rabies vaccination series for previously
vaccinated persons.

* Adapted from reference 1.
These regimens are applicable for all age groups, including children.
Day 0 is the day the first dose of vaccine is administered. Refer to vaccine manufacturer’s instructions or to the recommendations of the Advisory Committee on Immunization Practices (ACIP)(1-3) for appropriate rabies vaccine formulations, schedules and dosages.
§ Any person with a history of rabies vaccination and a documented history of antibody response to the prior vaccination.

2.2 Preparation

  • Calculate the volume of HYPERRAB for the recommended dose of 20 IU/kg.
  • Ensure the correct strength is used for the calculation. HYPERRAB is formulated with a strength of 300 IU/mL. The predecessor product, HYPERRAB S/D was formulated at 150 IU/mL. The volume required of HYPERRAB (300 IU/mL) to achieve the recommended dose of 20 IU/kg is approximately one half of that required for the previous HYPERRAB S/D (150 IU/mL).
  • Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. HYPERRAB is a clear or slightly opalescent, and colorless or pale yellow or light brown sterile solution.
  • Do not use HYPERRAB if the product shows any sign of tampering. Notify Grifols Therapeutics LLC immediately [1-800-520-2807].
  • Do not freeze. Do not use any solution that has been frozen.
  • Discard unused portion.

2.3 Administration

  • Administer HYPERRAB at the time of the first vaccine dose (day 0), but no later than day 7(1-3).
  • Infiltrate the full dose of HYPERRAB in the area around the wound, if anatomically feasible. Dilute HYPERRAB with an equal volume of dextrose, 5% (D5W), if additional volume is needed to infiltrate the entire wound. Do not dilute with normal saline.
  • Inject the remainder, if any, of the HYPERRAB dose intramuscularly into the deltoid muscle of the upper arm or into the lateral thigh muscle, and distant from the site of vaccine administration.
  • Do not administer HYPERRAB in the same syringe or needle or in the same anatomic site as vaccine.

10. Overdosage

Because Rabies Immune Globulin (Human) may partially suppress active production of antibody in response to the rabies vaccine, do not give more than the recommended dose of rabies immune globin (human).(1)

16.2. Storage and Handling

  • Store HYPERRAB at (2 to 8°C, 36 to 46°F).
  • Do not freeze.
  • Do not use after expiration date.
  • Discard unused portion.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.